Stock Track | Hims & Hers Health Soars 26% to Record High on Raised Forecasts, Weight Loss Drug Plans

Stock Track

Nov 12, 2024

Shares of telehealth company Hims & Hers Health Inc. (HIMS) surged as much as 26.35% to an all-time high of $29.68 on Friday, November 11th. The stock closed the trading session at $28.00, capping off a remarkable 213% gain for the year that significantly outperformed the broader market.

The rally was fueled by HIMS' raised full-year revenue forecast and its plans to enter the booming weight loss drug market. Last week, the company increased its 2024 revenue guidance to $1.46-$1.47 billion, up from the previous $1.37-$1.40 billion range. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss medication liraglutide to its platform in 2025.

With soaring demand leading to shortages of brand-name weight loss drugs like Novo's liraglutide and Eli Lilly's blockbuster Mounjaro, HIMS is well-positioned to capitalize on this lucrative market by producing generic alternatives under U.S. regulations. Analysts view the company's entry into the weight loss space as a significant growth opportunity, with TD Cowen raising its HIMS price target to $28 (from $25) on Monday and citing the liraglutide plans as a key driver.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1131805401"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131805401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131805401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 11:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131805401","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 26% to Record High on Raised Forecasts, Weight Loss Drug Plans","media":"Stock Track","content":"<p>Shares of telehealth company Hims & Hers Health Inc. (HIMS) surged as much as 26.35% to an all-time high of $29.68 on Friday, November 11th. The stock closed the trading session at $28.00, capping off a remarkable 213% gain for the year that significantly outperformed the broader market.</p>\n\n<p>The rally was fueled by HIMS' raised full-year revenue forecast and its plans to enter the booming weight loss drug market. Last week, the company increased its 2024 revenue guidance to $1.46-$1.47 billion, up from the previous $1.37-$1.40 billion range. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss medication liraglutide to its platform in 2025.</p>\n\n<p>With soaring demand leading to shortages of brand-name weight loss drugs like Novo's liraglutide and Eli Lilly's blockbuster Mounjaro, HIMS is well-positioned to capitalize on this lucrative market by producing generic alternatives under U.S. regulations. Analysts view the company's entry into the weight loss space as a significant growth opportunity, with TD Cowen raising its HIMS price target to $28 (from $25) on Monday and citing the liraglutide plans as a key driver.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 26% to Record High on Raised Forecasts, Weight Loss Drug Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 26% to Record High on Raised Forecasts, Weight Loss Drug Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-12 11:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of telehealth company Hims & Hers Health Inc. (HIMS) surged as much as 26.35% to an all-time high of $29.68 on Friday, November 11th. The stock closed the trading session at $28.00, capping off a remarkable 213% gain for the year that significantly outperformed the broader market.</p>\n\n<p>The rally was fueled by HIMS' raised full-year revenue forecast and its plans to enter the booming weight loss drug market. Last week, the company increased its 2024 revenue guidance to $1.46-$1.47 billion, up from the previous $1.37-$1.40 billion range. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss medication liraglutide to its platform in 2025.</p>\n\n<p>With soaring demand leading to shortages of brand-name weight loss drugs like Novo's liraglutide and Eli Lilly's blockbuster Mounjaro, HIMS is well-positioned to capitalize on this lucrative market by producing generic alternatives under U.S. regulations. Analysts view the company's entry into the weight loss space as a significant growth opportunity, with TD Cowen raising its HIMS price target to $28 (from $25) on Monday and citing the liraglutide plans as a key driver.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1131805401","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131805401","pubTimestamp":1731382961,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of telehealth company Hims & Hers Health Inc.  surged as much as 26.35% to an all-time high of $29.68 on Friday, November 11th. The stock closed the trading session at $28.00, capping off a remarkable 213% gain for the year that significantly outperformed the broader market.The rally was fueled by HIMS' raised full-year revenue forecast and its plans to enter the booming weight loss drug market. Last week, the company increased its 2024 revenue guidance to $1.46-$1.47 billion, up from the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票轨迹Hims&Hers Health因预测上调和减肥药计划而飙升26%，创历史新高","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of telehealth company Hims & Hers Health Inc. (HIMS) surged as much as 26.35% to an all-time high of $29.68 on Friday, November 11th. The stock closed the trading session at $28.00, capping off a remarkable 213% gain for the year that significantly outperformed the broader market.\nThe rally was fueled by HIMS' raised full-year revenue forecast and its plans to enter the booming weight loss drug market. Last week, the company increased its 2024 revenue guidance to $1.46-$1.47 billion, up from the previous $1.37-$1.40 billion range. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss medication liraglutide to its platform in 2025.\nWith soaring demand leading to shortages of brand-name weight loss drugs like Novo's liraglutide and Eli Lilly's blockbuster Mounjaro, HIMS is well-positioned to capitalize on this lucrative market by producing generic alternatives under U.S. regulations. Analysts view the company's entry into the weight loss space as a significant growth opportunity, with TD Cowen raising its HIMS price target to $28 (from $25) on Monday and citing the liraglutide plans as a key driver.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}